Donepezil Hydrochloride

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Dementia, Vascular

Conditions

Dementia, Vascular

Trial Timeline

Mar 1, 2003 → Jun 1, 2006

NCT ID

NCT00165737

About Donepezil Hydrochloride

Donepezil Hydrochloride is a phase 3 stage product being developed by Eisai for Dementia, Vascular. The current trial status is completed. This product is registered under clinical trial identifier NCT00165737. Target conditions include Dementia, Vascular.

What happened to similar drugs?

9 of 20 similar drugs in Dementia, Vascular were approved

Approved (9) Terminated (1) Active (10)

✅E2020 + PlaceboEisaiApproved

✅donepezil hydrochloride (Aricept)EisaiApproved

✅MecobalaminEisaiApproved

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅Risperdal,reminylJohnson & JohnsonApproved

✅ENA713NovartisApproved

✅Rivastigmine Patch 9.5 cm2NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02448784	Pre-clinical	Completed	Apr 20, 2015	Mar 30, 2017	Dementia With Lewy Body Disease
NCT02162264	Pre-clinical	Completed	Jun 1, 2013	Jul 22, 2016	Alzheimer's Disease
NCT02162251	Pre-clinical	Completed	Jun 1, 2013	Apr 15, 2016	Alzheimer's Desease
NCT01251718	Pre-clinical	Completed	Dec 1, 2010	Feb 18, 2016	Alzheimer's Disease
NCT01129596	Pre-clinical	Completed	Jun 10, 2010	Jun 23, 2016	Alzheimer's Disease
NCT00477659	Approved	Completed	Jul 23, 2007	Aug 15, 2008	Alzheimer's Disease
NCT00165750	Approved	Terminated	Mar 1, 2005	Nov 1, 2008	Alzheimer's Disease
NCT00165724	Approved	Completed	Jun 30, 2004	Dec 31, 2006	Alzheimer's Disease
NCT00165737	Phase 3	Completed	Mar 1, 2003	Jun 1, 2006	Dementia, Vascular
NCT00165659	Phase 2	Completed	Nov 1, 2002	—	Alzheimer Disease
NCT00096473	Phase 3	Completed	Jan 1, 2001	Sep 1, 2005	Alzheimer's Disease

Competing Products

20 competing products in Dementia, Vascular

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 3	26
AL001 + Placebo + Open label - AL001	Alector	Phase 3	22
AL001	Alector	Phase 2	25
ATH-1017 + Placebo	LeonaBio	Phase 2	17
IGC AD1 + Placebo	IGC Pharma	Phase 1	19
E2020 + Placebo	Eisai	Approved	43
ARICEPT	Eisai	Phase 3	40
Rasagiline	Eisai	Phase 2	35
Donepezil Hydrochloride	Eisai	Pre-clinical	26
donepezil hcl	Eisai	Phase 3	40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo	Eisai	Phase 3	40
E2020 + E2020	Eisai	Phase 2	35
donepezil hydrochloride (Aricept)	Eisai	Approved	43
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo	Eisai	Phase 2	35
E2020 + E2020	Eisai	Phase 3	40
Irsenontrine + Placebo	Eisai	Phase 2	35
E2020	Eisai	Phase 2	35
Mecobalamin	Eisai	Approved	43
E2020 + Placebo	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43